Search
Technetium Tc-99m sulfur colloid
go.drugbank.com/drugs/DB09397ApprovedThis is possible as Technetium-99m decays by isomeric transition to technetium-99 through the release of a gamma ray.
Cimetidine
go.drugbank.com/drugs/DB00501ApprovedInvestigationalIt inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant therapy.
Paritaprevir
go.drugbank.com/drugs/DB09297ApprovedInvestigationalParitaprevir is also available as a fixed-dose combination product with [DB09296] and [DB00503] as the FDA- and Health Canada-approved product Technivie. … Paritaprevir first came on the market as a fixed-dose combination product with [DB09296], [DB09183], and [DB00503] as the FDA-approved product Viekira Pak.
Asenapine
go.drugbank.com/drugs/DB06216ApprovedInvestigationalIt is also for severe post-traumatic stress disorder nightmares in soldiers as an off-label use. FDA approved on August 13, 2009.
Metocurine
go.drugbank.com/drugs/DB01336ApprovedDimethyltubocurarinium (INN) or metocurine (USAN), also known as dimethyltubocurarine, is a non-depolarizing muscle relaxant.
Iodixanol
go.drugbank.com/drugs/DB01249ApprovedIodixanol is a nonionic hydrophilic compound commonly used as a contrast agent during coronary angiography, particularly in individuals with renal dysfunction, as it is believed to be less toxic to the
Cemiplimab
go.drugbank.com/drugs/DB14707ApprovedInvestigational[L39804] Cemiplimab was first approved by the FDA on September 28, 2018, as the first FDA-approved treatment for advanced cutaneous squamous cell carcinoma (CSCC).
Sincalide
go.drugbank.com/drugs/DB09142ApprovedIt is identified as the 8-amino acid C-terminal segment of cholecystokinin and is also known as _CCK-8_. … [A261876] As the product Kinevac (FDA), sincalide is used to stimulate the duodenum, pancreas, and small bowel for cholesterol analysis, enzymatic activity analysis, and x-ray examination respectively
Pixantrone
go.drugbank.com/drugs/DB06193ApprovedWithdrawnIt also inhibits doxorubicinol formation in human myocardium. [3] As a result, it is believed to be less cardiotoxic while still exerting efficacy. … Pixantrone dimaleate, administered intravenously, was designed by Cell Therapeutics Incorporated as an alternative second line therapy in refractory or relapsed NHL.
Miglustat
go.drugbank.com/drugs/DB00419ApprovedInvestigationalMiglustat was first developed as an anti-HIV agent in the 1990s.